Skip to main content

Vivo Capital — Portfolio, Page 5

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

165
Companies
$12.4B
Total invested
$110.3M
Avg. check
19
Industries
Biotechnology 21Health Care 14Therapeutics 9Pharmaceutical 9Biopharma 7Medical 6+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 97120 of 165
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
IO Biotech
September 2025

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Biotechnology · Copenhagen$6.6M Post Ipo Equity
Semnur Pharmaceuticals
September 2025

Semnur Pharmaceuticals is a specialty pharmaceutical company focusing on clinical and commercial development of innovative products.

Biotechnology · Los Altos$100.0M Post Ipo Equity
Integra Therapeutics
September 2025

Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.

Biotechnology · Barcelona$3.2M Seed
Celcuity
September 2025

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Biotechnology · Hamel$500.0M Post Ipo Debt
Ronovo Surgical
September 2025

Ronovo Surgical is an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery.

Health Care · Shanghai$67.0M Series D
Compass Therapeutics
August 2025

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

Biopharma · Boston$120.0M Post Ipo Equity
Trevi Therapeutics
June 2025

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$115.1M Post Ipo Equity
ORIC Pharmaceuticals
May 2025

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Biopharma · South San Francisco$125.0M Post Ipo Equity
Surrozen
March 2025

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Biotechnology · South San Francisco$175.0M Post Ipo Equity
Tarsus Pharmaceuticals
March 2025

Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.

Biopharma · Irvine$125.0M Post Ipo Equity
Aligos Therapeutics
February 2025

Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.

Biotechnology · San Francisco$105.0M Post Ipo Equity
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoSeries Unknown
Neumirna Therapeutics
January 2025

Neumirna Therapeutics is a pharmaceutical company that develops therapeutics for the treatment of neurological diseases.

Health Care · Copenhagen$20.6M Series A
Chentai New Materials
December 2024

Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics.

Innovation Management · Suzhou$13.7M Series A
35Pharma
November 2024

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

Biopharma · Montreal$53.0M Series C
Harmony Biosciences
October 2024

Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.

Biopharma · Plymouth Meeting$248.0M Post Ipo Secondary
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post Ipo Equity
Serán Bioscience
September 2024

Serán Bioscience is a contract development and manufacturing organization.

Biotechnology · Bend$200.0M Private Equity
Lepu Bio
May 2024

Lepu Bio is a Innovation-Driven Biopharmaceutical Company offering unmet medical needs of cancer patients with best-in-class drugs.

Biotechnology · Shanghai$29.4M Post Ipo Equity
Ajax Therapeutics
May 2024

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

Biotechnology · Cambridge$95.0M Series C
Clasp Therapeutics
March 2024

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.

Biotechnology · Cambridge$150.0M Series A
ASLAN Pharmaceuticals
March 2024

ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.

Biotechnology · Singapore$5.0M Post Ipo Equity
Attralus
February 2024

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Biopharma · San Francisco$56.0M Series B

Where Vivo Capital invests

Biotechnology21
Health Care14
Therapeutics9
Pharmaceutical9
Biopharma7
Medical6

About Vivo Capital's portfolio

How many companies has Vivo Capital invested in?

Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Vivo Capital invest in?

Vivo Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Biopharma. The firm invests across 19 different industry categories.

What is Vivo Capital's largest investment?

Among tracked funding rounds, Celcuity received $500.0M in a Post Ipo Debt round. Vivo Capital's total known invested capital is $12.4B.

What is the average investment size for Vivo Capital?

Vivo Capital's average investment size is $110.3M across its portfolio of 165 companies.

What are Vivo Capital's most recent investments?

Recent Vivo Capital portfolio additions include Cidara Therapeutics, IO Biotech, Semnur Pharmaceuticals, Integra Therapeutics, Celcuity. These companies were founded in 2020 or later.

Reach the founders behind these 165 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →